|Bid||2.7300 x 1800|
|Ask||2.7400 x 1300|
|Day's Range||2.7200 - 2.8200|
|52 Week Range||2.2000 - 7.9400|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.10|
Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. Miragen Therapeutics Inc had annual average EBITDA growth of 4.00% over the past five years. Warning! GuruFocus has detected 3 Warning Signs with MGEN.
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo., March 13, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2018. “We are encouraged by the advances our team has made in the development of microRNA targeted therapies in 2018 and pleased to begin 2019 with three clinical stage product candidates being evaluated in five clinical trials for the potential to treat patients who suffer from a variety of diseases with high unmet medical need.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics. “In addition to the release of encouraging clinical data for cobomarsen in cutaneous T-cell lymphoma (CTCL), we have also seen exciting preliminary clinical activity for cobomarsen in other blood cancers and have also advanced the development of remlarsen into a Phase 2 clinical trial in cutaneous fibrosis.
BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20 in New York City.
BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2018. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com. A replay of this conference call will be available on miRagen’s website approximately one hour after the event.
When it comes to top biotech clusters in the country, Colorado is in the conversation, but has a way to go to be mentioned in the same breath as California and Massachusetts, where a majority of investor money goes into drug development. “I’d say it’s really on fire right now,” said Frank Segrave, CEO of Silvergate Pharmaceuticals. “Part of that is all the really good collaboration between the state, the academic institutions and the business community, but it’s also the economy here, the quality of life that’s really building up the industry here.” Home to about 720 bioscience firms, a majority of which are in a pre-revenue stage, the industry here is making a concentrated push to attract more investment so that more companies can complete research and bring drugs and medical devices to market.
50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization.
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it will present new data from its Phase 1 trial of cobomarsen in HTLV-1 associated adult T-cell leukemia/lymphoma (ATLL) as well as its Phase 1 trial of cobomarsen in patients with mycosis fungoides, the most common form of cutaneous T-cell (CTCL) at the 11th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 10th-12th.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the Board of Directors. Mr. Hatfield succeeds Bruce Booth, DPhil., who is stepping down in order to focus on making new investments in the Atlas Venture portfolio. Additionally, current Director Arlene Morris will replace Dr. Booth on the audit committee. The Board will be comprised of seven directors, including six non-executive directors.
“We are excited to present final data from our Phase 1 cobomarsen clinical trial, which continue to show that cobomarsen is safe and well-tolerated, has relevant biological and clinical activity in patients and has the potential to impact the quality of life for MF patients,” stated miRagen Executive Vice President, R&D, Paul Rubin. The Phase 1 clinical trial investigated the safety, tolerability, PK, PD and efficacy of cobomarsen in a total of 43 MF patients. Cobomarsen was initially administered via intratumoral injection (75 mg/dose), and then via systemic administration by subcutaneous (SC), intravenous (IV) bolus or IV infusion, at 300, 600 or 900 mg/dose with loading doses in the first week followed by weekly maintenance dosing.
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 9.38% and -50.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Continued advancements of three clinical stage microRNA-targeted product candidates currently being evaluated for multiple potential indications in four clinical trialsGlobal.
BOULDER, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that new data from its Phase 1 trial of cobomarsen, an inhibitor of miR-155, in patients with mycosis fungoides, the most common form of cutaneous T cell lymphoma, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting, which is being held in San Diego, CA, from December 1st – 4th.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Miragen Therapeutics, Inc. (NASDAQ: MGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...